View More Recent Stories

Jan 6, 2020 04:08PM Xeris Pharma (XERS) Announces Positive Results from In-Clinic Stage of Phase 2 Study of Its Developmental RTU Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise
Jan 6, 2020 04:05PM Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerob
Dec 27, 2019 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 27, 2019 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 10, 2019 05:34PM Xeris Pharmaceuticals (XERS) Announces Positive Topline Results From the In-clinic Stage of Phase 2 Study of RTU Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery
Dec 10, 2019 05:33PM Xeris Pharmaceuticals Announces Positive Topline Results From the In-clinic Stage of the Phase 2 Study of Its Developmental Ready-to-use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia
Nov 29, 2019 01:05PM Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 29, 2019 01:05PM Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 21, 2019 06:18AM Xeris Pharmaceuticals Inc. (XERS) Provides Business Update During Recent Investor Conference
Nov 21, 2019 06:00AM Xeris Pharmaceuticals Provides a Business Update During Recent Investor Conference
Nov 21, 2019 06:00AM Xeris Pharmaceuticals Provides a Business Update During Recent Investor Conference
Nov 7, 2019 08:00AM Xeris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights
Nov 7, 2019 08:00AM Xeris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights
Nov 1, 2019 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 1, 2019 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 1, 2019 08:09AM Xeris Pharmaceuticals Inc. (XERS) Names Mark Thierer to Board
Oct 1, 2019 08:00AM Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors
Oct 1, 2019 08:00AM Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors
Sep 27, 2019 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 27, 2019 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 19, 2019 08:06AM Xeris Pharmaceuticals Inc. (XERS) Commences Patient Dosing in Ph. 2 Clinical Trial Evaluating Fixed-Ratio Co-Formulation of Pramlintide-Insulin for Diabetes
Sep 19, 2019 08:00AM Xeris Pharmaceuticals Begins Dosing Patients in a Phase 2 Clinical Trial Evaluating Its Novel Fixed-Ratio Co-Formulation of Pramlintide-Insulin for Diabetes
View More Recent Stories